Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.48 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13193072 | 0.85 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL27544844 | 0.83 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL15271409 | 0.83 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL30848490 | 0.82 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL15983801 | 0.81 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL29954061 | 0.80 | CTSD (0.55) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL457993 | 0.77 | NPC1 (0.84) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL13638925 | 0.77 | HSD17B10 (0.70) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL13888629 | 0.77 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL13638867 | 0.76 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140255392-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
| US-20140255392-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140255392-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | FLT4, KDR, VEGFA | NPC1 2593/4885RAB9A 2032/4885SMN1; SMN2 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.